Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
Harvard Bioscience (HBIO) reported Q4 2024 revenues of $24.6 million, down from $28.2 million in Q4 2023. The company achieved a Q4 gross margin of 57.1% and posted a minimal net income of $18,000, improving from a $1.8 million loss in Q4 2023.
For full-year 2024, revenues declined to $94.1 million from $112.3 million in 2023, with a gross margin of 58.2%. The company recorded a net loss of $12.4 million for 2024, compared to a $3.4 million loss in 2023. The decline was attributed to challenging global market conditions and reduced spending by CROs, distributors, and academic institutions.
Looking ahead, HBIO projects Q1 2025 revenues between $19-21 million with gross margins of 56-58%, citing uncertainty in NIH funding and academic research purchasing.
Harvard Bioscience (HBIO) ha riportato ricavi nel Q4 2024 pari a 24,6 milioni di dollari, in calo rispetto ai 28,2 milioni di dollari nel Q4 2023. L'azienda ha raggiunto un margine lordo del Q4 del 57,1% e ha registrato un reddito netto minimo di 18.000 dollari, migliorando rispetto a una perdita di 1,8 milioni di dollari nel Q4 2023.
Per l'intero anno 2024, i ricavi sono scesi a 94,1 milioni di dollari rispetto ai 112,3 milioni di dollari del 2023, con un margine lordo del 58,2%. L'azienda ha registrato una perdita netta di 12,4 milioni di dollari per il 2024, rispetto a una perdita di 3,4 milioni di dollari nel 2023. Il calo è stato attribuito a condizioni di mercato globali difficili e a una riduzione della spesa da parte di CRO, distributori e istituzioni accademiche.
Guardando al futuro, HBIO prevede ricavi nel Q1 2025 compresi tra 19-21 milioni di dollari con margini lordi del 56-58%, citando incertezze nel finanziamento del NIH e negli acquisti di ricerca accademica.
Harvard Bioscience (HBIO) reportó ingresos de 24,6 millones de dólares en el Q4 2024, una disminución respecto a los 28,2 millones de dólares en el Q4 2023. La compañía logró un margen bruto del Q4 del 57,1% y reportó un ingreso neto mínimo de 18.000 dólares, mejorando de una pérdida de 1,8 millones de dólares en el Q4 2023.
Para el año completo 2024, los ingresos cayeron a 94,1 millones de dólares desde 112,3 millones de dólares en 2023, con un margen bruto del 58,2%. La empresa registró una pérdida neta de 12,4 millones de dólares para 2024, en comparación con una pérdida de 3,4 millones de dólares en 2023. La disminución se atribuyó a las difíciles condiciones del mercado global y a la reducción del gasto por parte de CROs, distribuidores e instituciones académicas.
De cara al futuro, HBIO proyecta ingresos para el Q1 2025 entre 19-21 millones de dólares con márgenes brutos del 56-58%, citando incertidumbre en la financiación del NIH y en las compras de investigación académica.
하버드 바이오사이언스 (HBIO)는 2024년 4분기 매출이 2460만 달러로, 2023년 4분기 2820만 달러에서 감소했다고 보고했습니다. 회사는 4분기 총 마진이 57.1%를 기록했으며, 2023년 4분기의 180만 달러 손실에서 개선된 1만8000 달러의 최소 순이익을 기록했습니다.
2024년 전체 매출은 2023년 1억1230만 달러에서 9410만 달러로 감소했으며, 총 마진은 58.2%입니다. 회사는 2024년에 1240만 달러의 순손실을 기록했으며, 이는 2023년의 340만 달러 손실과 비교됩니다. 감소는 글로벌 시장의 어려운 조건과 CRO, 유통업체 및 학술 기관의 지출 감소에 기인했습니다.
앞으로 HBIO는 2025년 1분기 매출이 1900만-2100만 달러 사이가 될 것으로 예상하며, 총 마진은 56-58%로, NIH 자금 지원 및 학술 연구 구매에 대한 불확실성을 언급했습니다.
Harvard Bioscience (HBIO) a rapporté des revenus de 24,6 millions de dollars pour le Q4 2024, en baisse par rapport à 28,2 millions de dollars au Q4 2023. L'entreprise a atteint une marge brute de 57,1 % pour le Q4 et a affiché un revenu net minimal de 18 000 dollars, s'améliorant par rapport à une perte de 1,8 million de dollars au Q4 2023.
Pour l'année complète 2024, les revenus ont diminué à 94,1 millions de dollars contre 112,3 millions de dollars en 2023, avec une marge brute de 58,2 %. L'entreprise a enregistré une perte nette de 12,4 millions de dollars pour 2024, contre une perte de 3,4 millions de dollars en 2023. La baisse a été attribuée à des conditions de marché mondiales difficiles et à une réduction des dépenses par les CRO, les distributeurs et les institutions académiques.
En regardant vers l'avenir, HBIO prévoit des revenus pour le Q1 2025 compris entre 19-21 millions de dollars avec des marges brutes de 56-58 %, citant des incertitudes concernant le financement du NIH et les achats de recherche académique.
Harvard Bioscience (HBIO) berichtete für das 4. Quartal 2024 von Einnahmen in Höhe von 24,6 Millionen Dollar, ein Rückgang von 28,2 Millionen Dollar im 4. Quartal 2023. Das Unternehmen erreichte eine Bruttomarge von 57,1% im 4. Quartal und verzeichnete einen minimalen Nettogewinn von 18.000 Dollar, eine Verbesserung gegenüber einem Verlust von 1,8 Millionen Dollar im 4. Quartal 2023.
Für das Gesamtjahr 2024 sanken die Einnahmen auf 94,1 Millionen Dollar von 112,3 Millionen Dollar im Jahr 2023, mit einer Bruttomarge von 58,2%. Das Unternehmen verzeichnete einen Nettoverlust von 12,4 Millionen Dollar für 2024, im Vergleich zu einem Verlust von 3,4 Millionen Dollar im Jahr 2023. Der Rückgang wurde auf herausfordernde globale Marktbedingungen und reduzierte Ausgaben von CROs, Vertriebspartnern und akademischen Institutionen zurückgeführt.
Für die Zukunft prognostiziert HBIO Einnahmen im 1. Quartal 2025 zwischen 19-21 Millionen Dollar mit Bruttomargen von 56-58%, wobei Unsicherheiten bei der NIH-Finanzierung und den Einkäufen in der akademischen Forschung angeführt werden.
- Improved Q4 net income to $18,000 from -$1.8 million loss year-over-year
- Strong market reception for new SoHo™ and MeshMEA™ product lines
- Maintained healthy gross margins above 57% despite revenue decline
- Positive operating cash flow of $1.7 million in Q4 2024
- Q4 2024 revenue declined 12.8% to $24.6 million vs $28.2 million in Q4 2023
- Full-year 2024 revenue dropped 16.2% to $94.1 million from $112.3 million
- Net loss widened to $12.4 million in 2024 from $3.4 million in 2023
- Operating cash flow decreased to $1.4 million in 2024 from $14.0 million in 2023
- Reduced purchasing from US academic customers impacting CMT revenues
Insights
Harvard Bioscience's Q4 and full-year 2024 results reveal significant financial deterioration that should concern investors. The company reported
The company's cash generation capability has severely weakened with operating cash flow plummeting to
While management highlighted "strong market reception" for new products like SoHo™ telemetry and MeshMEA™ organoid systems, these positive developments haven't translated to financial performance. The Q1 2025 guidance of
The slight Q4 net income of
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024.
Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment.
Green continued, “We are encouraged by the strong market reception of our new products by prominent academic institutions, contract research organizations and biopharma customers. In particular, we are seeing strong interest in our new SoHo™ telemetry systems and emerging growth of our breakthrough MeshMEA™ organoid systems. Finally, in the current market uncertainty, we remain focused on managing costs to improve our operating and financial performance.”
Fourth Quarter 2024 Results
For the fourth quarter of fiscal 2024, the Company reported revenues of
Net income for the fourth quarter of 2024 was
Results for Year Ended December 31, 2024
For the year ended December 31, 2024, revenues were
Net loss for the year ended December 31, 2024 was (
This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Q1 2025 Guidance
Given the prevailing uncertainty in NIH funding and academic research purchasing, along with normal seasonality, the Company expects Q1 2025 revenues of
Webcast and Conference Call Details
In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to the Company’s Investor Relations website shortly before the webcast begins.
Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Use of Non-GAAP Financial Information
In this press release we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of our business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, other operating expenses, loss on equity securities, income taxes, and the tax impact of reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.
Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included below in this press release.
With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation may not be subject to the control of or may not be reliably predicted by management. These items could cause our non-GAAP forward looking measures to vary materially from measures reported under GAAP.
The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margin, adjusted EBITDA and adjusted EBITDA margin, cash and debt position, growth and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic conditions, and matters relating to our ability to continue as a going concern, fund our operations, or refinance our outstanding indebtedness. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
Jennifer Cote
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
| HARVARD BIOSCIENCE, INC. | ||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues | $ | 24,556 | $ | 28,153 | $ | 94,135 | $ | 112,250 | ||||||||
| Cost of revenues | 10,545 | 11,828 | 39,369 | 46,179 | ||||||||||||
| Gross profit | 14,011 | 16,325 | 54,766 | 66,071 | ||||||||||||
| Sales and marketing expenses | 5,395 | 6,171 | 22,212 | 24,060 | ||||||||||||
| General and administrative expenses | 4,803 | 5,263 | 21,493 | 22,757 | ||||||||||||
| Research and development expenses | 2,328 | 3,150 | 10,406 | 11,764 | ||||||||||||
| Amortization of intangible assets | 1,257 | 1,387 | 5,255 | 5,525 | ||||||||||||
| Other operating expenses | 217 | 71 | 1,611 | 71 | ||||||||||||
| Total operating expenses | 14,000 | 16,043 | 60,977 | 64,177 | ||||||||||||
| Operating income (loss) | 11 | 282 | (6,211 | ) | 1,894 | |||||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (853 | ) | (794 | ) | (3,209 | ) | (3,591 | ) | ||||||||
| Loss on equity securities | - | (259 | ) | (1,593 | ) | (632 | ) | |||||||||
| Other income (expense), net | 1,432 | (332 | ) | (652 | ) | (227 | ) | |||||||||
| Total other income (expense) | 579 | (1,385 | ) | (5,454 | ) | (4,450 | ) | |||||||||
| Income (loss) before income taxes | 590 | (1,103 | ) | (11,665 | ) | (2,556 | ) | |||||||||
| Income tax expense | 572 | 715 | 740 | 859 | ||||||||||||
| Net income (loss) | $ | 18 | $ | (1,818 | ) | $ | (12,405 | ) | $ | (3,415 | ) | |||||
| Earnings (loss) per share: | ||||||||||||||||
| Basic earnings (loss) per share | $ | 0.00 | $ | (0.04 | ) | $ | (0.28 | ) | $ | (0.08 | ) | |||||
| Diluted earnings (loss) per share | $ | 0.00 | $ | (0.04 | ) | $ | (0.28 | ) | $ | (0.08 | ) | |||||
| Weighted-average common shares: | ||||||||||||||||
| Basic | 43,659 | 42,710 | 43,538 | 42,420 | ||||||||||||
| Diluted | 44,454 | 42,710 | 43,538 | 42,420 | ||||||||||||
| HARVARD BIOSCIENCE, INC. | ||||||
| Condensed Consolidated Balance Sheets | ||||||
| (in thousands) | ||||||
| December 31, | ||||||
| 2024 | 2023 | |||||
| Assets | ||||||
| Cash and cash equivalents | $ | 4,108 | $ | 4,283 | ||
| Accounts receivable, net | 14,866 | 16,099 | ||||
| Inventories | 23,245 | 24,716 | ||||
| Other current assets | 2,898 | 3,940 | ||||
| Total current assets | 45,117 | 49,038 | ||||
| Property, plant and equipment | 5,106 | 3,981 | ||||
| Goodwill and other intangibles | 67,456 | 73,101 | ||||
| Other long-term assets | 8,965 | 11,246 | ||||
| Total assets | $ | 126,644 | $ | 137,366 | ||
| Liabilities and Stockholders' Equity | ||||||
| Current portion, long-term debt | $ | 36,956 | $ | 5,859 | ||
| Other current liabilities | 18,002 | 20,683 | ||||
| Total current liabilities | 54,958 | 26,542 | ||||
| Long-term debt, net | - | 30,704 | ||||
| Other long-term liabilities | 8,346 | 7,046 | ||||
| Stockholders’ equity | 63,340 | 73,074 | ||||
| Total liabilities and stockholders’ equity | $ | 126,644 | $ | 137,366 | ||
| HARVARD BIOSCIENCE, INC. | |||||||||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||||||||
| (in thousands) | |||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||
| December 31, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | ||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income (loss) | $ | 18 | $ | (1,818 | ) | $ | (12,405 | ) | $ | (3,415 | ) | ||||
| Adjustments to operating cash flows | 2,300 | 3,732 | 13,780 | 12,843 | |||||||||||
| Changes in operating assets and liabilities | (593 | ) | 2,389 | 65 | 4,600 | ||||||||||
| Net cash provided by operating activities | 1,725 | 4,303 | 1,440 | 14,028 | |||||||||||
| Cash flows from investing activities: | |||||||||||||||
| Additions to property, plant and equipment | (301 | ) | (830 | ) | (2,644 | ) | (1,788 | ) | |||||||
| Acquisition of intangible assets | (165 | ) | (231 | ) | (619 | ) | (523 | ) | |||||||
| Proceeds from sale of product line | - | - | - | 512 | |||||||||||
| Proceeds from sale of marketable equity securities | - | - | 1,919 | - | |||||||||||
| Net cash used in investing activities | (466 | ) | (1,061 | ) | (1,344 | ) | (1,799 | ) | |||||||
| Cash flows from financing activities: | |||||||||||||||
| Borrowing from revolving line of credit | - | 1,000 | 8,800 | 4,500 | |||||||||||
| Repayment of revolving line of credit | - | (2,500 | ) | (2,550 | ) | (10,950 | ) | ||||||||
| Repayment of term debt | (1,000 | ) | (750 | ) | (6,023 | ) | (4,091 | ) | |||||||
| Payment of debt issuance costs | - | - | (161 | ) | - | ||||||||||
| Proceeds from exercise of employee stock options and purchases | 161 | 206 | 380 | 930 | |||||||||||
| Taxes paid related to net share settlement of equity awards | (518 | ) | (2,072 | ) | (577 | ) | (2,523 | ) | |||||||
| Net cash used in financing activities | (1,357 | ) | (4,116 | ) | (131 | ) | (12,134 | ) | |||||||
| Effect of exchange rate changes on cash and cash equivalents | (363 | ) | (183 | ) | (140 | ) | (320 | ) | |||||||
| Decrease in cash and cash equivalents | (461 | ) | (1,057 | ) | (175 | ) | (225 | ) | |||||||
| Cash and cash equivalents at the beginning of period | 4,569 | 5,340 | 4,283 | 4,508 | |||||||||||
| Cash and cash equivalents at the end of period | $ | 4,108 | $ | 4,283 | $ | 4,108 | $ | 4,283 | |||||||
| HARVARD BIOSCIENCE, INC. | |||||||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) | |||||||||||||||||||
| (in thousands, except per share data and percentages) | |||||||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||||||
| December 31, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | ||||||||||||||||
| GAAP operating income (loss) | $ | 11 | $ | 282 | $ | (6,211 | ) | $ | 1,894 | ||||||||||
| Stock-based compensation | 961 | 1,382 | 4,340 | 5,000 | |||||||||||||||
| Acquired asset amortization | 1,257 | 1,387 | 5,255 | 5,525 | |||||||||||||||
| Other operating expenses (1) | 217 | 71 | 1,611 | 71 | |||||||||||||||
| Other adjustments | 42 | 136 | 299 | 585 | |||||||||||||||
| Adjusted operating income | $ | 2,488 | $ | 3,258 | $ | 5,294 | $ | 13,075 | |||||||||||
| Operating margin | 0.0 | % | 1.0 | % | (6.6 | %) | 1.7 | % | |||||||||||
| Adjusted operating margin | 10.1 | % | 11.6 | % | 5.6 | % | 11.7 | % | |||||||||||
| GAAP net income (loss) (2) | $ | 18 | $ | (1,818 | ) | $ | (12,405 | ) | $ | (3,415 | ) | ||||||||
| Stock-based compensation | 961 | 1,382 | 4,340 | 5,000 | |||||||||||||||
| Acquired asset amortization | 1,257 | 1,387 | 5,255 | 5,525 | |||||||||||||||
| Other operating expenses (1) | 217 | 71 | 1,611 | 71 | |||||||||||||||
| Other adjustments | 42 | 136 | 299 | 182 | |||||||||||||||
| Loss on equity securities | - | 258 | 1,593 | 632 | |||||||||||||||
| Income taxes | 191 | 315 | 568 | (1,604 | ) | ||||||||||||||
| Adjusted net income | 2,686 | 1,731 | 1,261 | 6,391 | |||||||||||||||
| Depreciation & amortization | 503 | 393 | 1,902 | 1,476 | |||||||||||||||
| Interest and other expense, net (2) | (579 | ) | 1,126 | 3,861 | 4,221 | ||||||||||||||
| Adjusted income taxes (3) | 381 | 400 | 172 | 2,463 | |||||||||||||||
| Adjusted EBITDA | $ | 2,991 | $ | 3,650 | $ | 7,196 | $ | 14,551 | |||||||||||
| Adjusted EBITDA margin | 12.2 | % | 13.0 | % | 7.6 | % | 13.0 | % | |||||||||||
| Diluted earnings (loss) per share (GAAP) | $ | 0.00 | $ | (0.04 | ) | $ | (0.28 | ) | $ | (0.08 | ) | ||||||||
| Diluted adjusted earnings per share | $ | 0.06 | $ | 0.04 | $ | 0.03 | $ | 0.14 | |||||||||||
| Weighted-average common shares: | |||||||||||||||||||
| Diluted GAAP | 43,659 | 42,710 | 43,538 | 42,420 | |||||||||||||||
| Diluted Adjusted | 44,454 | 44,819 | 44,391 | 44,361 | |||||||||||||||
| December 31, | |||||||||||||||||||
| 2024 | 2023 | ||||||||||||||||||
| Debt, including unamortized deferred financing costs | $ | 36,956 | $ | 36,563 | |||||||||||||||
| Unamortized deferred financing costs | 394 | 560 | |||||||||||||||||
| Cash and cash equivalents | (4,108 | ) | (4,283 | ) | |||||||||||||||
| Net debt | $ | 33,242 | $ | 32,840 | |||||||||||||||
| (1) Other operating expenses for the three months ended December 31, 2024 includes | |||||||||||||||||||
| (2) GAAP net income for the three months ended December 31, 2024, includes the correction of an immaterial error associated with recording a loss on pension settlement in the unaudited interim financial statements for the three months ended September 30, 2024. The correction overstates GAAP net income by | |||||||||||||||||||
| (3) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise. | |||||||||||||||||||
FAQ
What were Harvard Bioscience's (HBIO) Q4 2024 financial results?
How much did Harvard Bioscience's (HBIO) revenue decline in 2024?
What is HBIO's revenue guidance for Q1 2025?
What caused Harvard Bioscience's revenue decline in 2024?
How did HBIO's new products perform in the market?
